drugset / Trial / NCT05727657
Satralizumab in Aneurysmal Subarachnoid Hemorrhage
NaSingle-groupOpen-labelTreatment
Summary
In this study, satralizumab will be administered to see whether satralizumab is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.
Timeline
- Start
- 2024-06
- Primary completion
- 2024-06-24
- Completion
- 2024-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Satralizumab | Monoclonal antibody | 120 mg | Subcutaneous |